Circulating microRNA expression profiles as biomarkers of disease activity in multiple sclerosis
Multiple Sclerosis Journal - Experimental, Translational and Clinical · Published 2026-07-01 · DOI 10.1177/20552173261471723
Free full text
Authors (7)
Ifat Vigiser, Yoav Zeevi, Yoav Piura, Hadar Kolb, Maya Golan, Arnon Karni, Keren Regev
Abstract
Background Reliable biomarkers of inflammatory activity in multiple sclerosis (MS) are needed to complement clinical and MRI assessments. Circulating microRNAs (miRNAs) are promising candidates due to their serum stability and involvement in MS-related biological pathways. Objectives To evaluate whether selected serum miRNAs can discriminate relapse from remission in treatment-naive patients with relapsing-remitting MS (RRMS). Methods In this prospective paired study, newly diagnosed, untreated RRMS patients were sampled during clinical relapse and subsequent remission. A targeted miRNA panel was quantified using quantitative PCR. Differential expressions were assessed using paired statistical testing with multiple comparison correction. Diagnostic performance was evaluated using ROC analysis and multivariate logistic regression. Pathway enrichment analysis was performed using Ingenuity Pathway Analysis. Results Twenty patients (40 paired samples) were included. Eight miRNAs were differentially expressed between relapse and remission after Benjamini–Hochberg correction. hsa-miR-122-5p showed the largest fold change (fold change = 3.0; adjusted p = 0.043). A three-miRNA panel (hsa-miR-122-5p, hsa-miR-15b-5p, hsa-miR-30e-5p) demonstrated high discriminative accuracy (area under the curve = 0.88; 95% CI 0.79–0.96). Pathway analysis highlighted inflammatory, metabolic, and hypoxia-related processes. Conclusions Circulating miRNAs distinguished relapse from remission in treatment-naive RRMS patients, suggesting their potential as complementary biomarkers of disease activity. These findings should be considered exploratory and require validation in an independent, larger cohort.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Publication details
- Year
- 2026
Citation
Vigiser, I., Zeevi, Y., Piura, Y., et al. (2026). Circulating microRNA expression profiles as biomarkers of disease activity in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical. https://doi.org/10.1177/20552173261471723
Related articles
- Comorbidities in newly diagnosed multiple sclerosis patients: A population-based register study in Finland · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Hypogammaglobulinemia and infection rates in patients with multiple sclerosis treated with ocrelizumab for up to six years: A real-world single-center study · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2025 · Same journal
- Real-world safety and effectiveness of ofatumumab in multiple sclerosis: A clinic-based study in Australia · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Men's health research priorities in men with multiple sclerosis · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Music therapy with a monochord in multiple sclerosis (“MUTIMS”): A randomized, controlled, rater-blinded trial · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2025 · Same journal
- Deep cervical lymph node volume decreases following B-cell depletion therapy · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2025 · Same journal
- Establishing demographic-based normative values for neurofilament light chain and glial fibrillary acidic protein in serum and plasma samples · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Feasibility and preliminary outcomes of a remotely-delivered exercise training intervention for English-speaking Hispanics/Latinos with multiple sclerosis: Results from the FERLA MS study · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Discrepancy between subjective and objective cognitive function in multiple sclerosis and association with mood, fatigue, and pain · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Baricitinib triggering a central nervous system inflammatory-demyelinating disease: A case report · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal